Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
F. Baert,G. D'Haens,5 Authors,P. Rutgeerts
1999 · DOI: 10.1016/S0016-5085(99)70224-6
Gastroenterology · 457 Citations
TLDR
Signs of active inflammation nearly disappear accompanied by a profound down-regulation of mucosal inflammatory mediators in Crohn's ileocolitis after infliximab dramatically decreases histological disease activity.